Abstract. Glycogen synthase 2 (Gys-2) is the ratelimiting enzyme in the storage of glycogen in liver and adipose tissue, yet little is known about regulation of Gys-2 transcription. The peroxisome proliferator-activated receptors (PPARs) are transcription factors involved in the regulation of lipid and glucose metabolism and might be hypothesized to govern glycogen synthesis as well. Here, we show that Gys-2 is a direct target gene of PPARa, PPARb/d and PPARg. Expression of Gys-2 is significantly reduced in adipose tissue of PPARa-/-, PPARb/d-/-and PPARg+/-mice. Furthermore, synthetic PPARb/d, and g agonists markedly up-regulate Gys-2 mRNA and protein expression in mouse 3T3-L1 adipocytes. In liver, PPARa deletion leads to decreased glycogen levels in the refed state, which is paralleled by decreased expression of Gys-2 in fasted and refed state. Two putative PPAR response elements (PPREs) were identified in the mouse Gys-2 gene: one in the upstream promoter (DR-1prom) and one in intron 1 (DR-1int). It is shown that DR-1int is the response element for PPARs, while DR-1prom is the response element for Hepatic Nuclear Factor 4 alpha (HNF4a). In adipose tissue, which does not express HNF4a, DR-1prom is occupied by PPARb/d and PPARg, yet binding does not translate into transcriptional activation of Gys-2. Overall, we conclude that mouse Gys-2 is a novel PPAR target gene and that transactivation by PPARs and HNF4a is mediated by two distinct response elements.
different tissue distribution and ligand specificity [1] . PPARs share a similar structure and a common molecular mechanism of action by forming an obligate heterodimer with the 9-cis retinoic acid receptor RXR. PPAR-RXR heterodimers selectively bind genomic sequences consisting of a direct repeat of the hexameric nucleotide sequence AGGTCA separated by 1 nucleotide (Direct Repeat-1). These socalled peroxisome proliferator response elements (PPRE) are located in the promoter of PPAR target genes or in intronic regions [2] [3] [4] [5] . The PPARa isotype (NR1C1) is highly expressed in liver, and governs the adaptive response to fasting [6] [7] [8] . PPARa is an extremely important regulator of hepatic nutrient metabolism including fatty acid oxidation (peroxisomal and mitochondrial), fatty acid uptake, amino acid metabolism, glycerol metabolism, and lipoprotein assembly and transport [9] [10] [11] . In addition, PPARa potently suppresses the hepatic inflammatory response [12, 13] , an effect that is also observed in extra-hepatic tissues such as the vascular wall [14] . Much less is known about the role of PPARa in other tissues, although evidence is accumulating that PPARa induces cardiac and skeletal muscle fatty acid oxidation [15, 16] . Importantly, PPARa mediates the effects of hypolipidemic fibrate drugs, which decrease plasma triglycerides and increase plasma HDL concentrations. In contrast to PPARa, PPARg (NR1C3) is highly expressed in white adipose tissue (WAT), where it promotes lipid storage. PPARg is a key transcription factor in the adipogenesis program and is essential for adipocyte survival [17, 18] . It also serves as the molecular target for the thiazolidinedione (TZD) class of insulin-sensitizing drugs that are widely used in the treatment of type 2 diabetes. PPARg promotes whole body glucose utilization; however, it has been difficult to identify the molecular mechanisms behind this effect. Much of the attention has been focused on possible cross-talk between adipose tissue and skeletal muscle, as muscle is responsible for the major share of whole body glucose utilization. However, adipose tissue is a large organ, especially in the obese, and accordingly it can also be envisioned that the insulin-sensitizing effect of TZDs on glucose uptake is partially exerted at the adipose tissue level. While PPARa and PPARg have been extensively studied over many years, much less is known about the function of the PPARb/d isotype (NR1C2). Studies with genetically modified PPARb/d mice have illustrated the importance of this nuclear receptor in WAT and skeletal muscle, two organs that have a key role in glucose homeostasis [19] [20] [21] [22] . It was shown that activation of PPARb/d in adipose tissue protects against adiposity and hyperlipidemia by inducing fatty acid catabolism [21] . Moreover, pharmacological activation as well as specific constitutive overexpression of PPARb/d leads to a shift in muscle fiber composition towards type I muscle fibers, resulting in increased muscle oxidative capacity [20, 22] . PPARb/ d has also been shown to stimulate hepatic VLDL production, influence wound healing, and affect colon carcinogenesis [23] [24] [25] . However, whether PPARb/d has a functional role in glucose homeostasis, in analogy with other PPAR isotypes, remains to be firmly established. Here we show that glycogen synthase 2 (Gys-2), the rate-limiting enzyme for glycogen synthesis in liver and adipose tissue, is a target gene of PPARa, PPARb/ d and PPARg. Transcriptional regulation is achieved via a PPAR response element present in the first intron. We show that an additional direct repeat response element identified in the Gys-2 promoter mediates transactivation by hepatic nuclear factor 4a (HNF4a).
Materials and methods
Chemicals. Wy14643 was obtained from Eagle Picher Technologies laboratories (Lenexa, KS, USA). Rosiglitazone was from Alexis (Breda, The Netherlands). SYBR Green was from Eurogentec (Seraing, Belgium). Dulbeccos modified Eagles medium (DMEM), fetal calf serum (FCS), calf serum and penicillin/streptomycin/ fungizone were from Cambrex Bioscience (Seraing). Otherwise, chemicals were from Sigma (Zwijndrecht, The Netherlands). Animal experiments. PPARb/d mutant null mice (PPARb/d-/-) and PPARg heterozygous mice (PPARg+/-) were on a mixed background (Sv129/C57BL/6) and have been described previously [26, 27] . Wild-type littermates served as control animals. PPARa-/-mice and corresponding wild-type mice on an Sv129 background were purchased at Jackson Laboratories (Bar Harbor, ME, USA). Liver-specific hepatocyte nuclear factor 4a (HNF4a)-null mice were generated as described previously. Livers were collected from 45-day-old HNF4a flox/flox X albumin-Cre + (KO) and HNF4a flox/flox X albumin-Cre -(FLOX) mice [28] . Mice were maintained at 208C with a 12-h light-dark cycle. All mice were between 3 and 6 months of age. For the fasting experiment, 3-month-old male mice were fasted for different periods of time starting at the onset of the light cycle. For the refeeding experiment, mice were fasted for 24 h after which they were put back on chow for 7 h before sacrifice. After sacrificing the animals, tissues were immediately frozen in liquid nitrogen. The animal experiments were approved by the animal experimentation committee of Wageningen University or the Etat de Vaud (Switzerland). Oligonucleotide micro-array. Total RNA was prepared from epididymal WAT of wild-type and PPARb/d-/-mice (five animals of each genotype) using TRIzol reagent (Invitrogen, Breda, The Netherlands) and subsequently pooled per group. Pooled RNAwas further purified using Qiagen RNeasy columns, and the quality was verified using Bioanalyzer 2100 (Agilent, Amsterdam). For one cycle cRNA synthesis (Affymetrix, Santa Clara, USA) 10 mg of RNA was used. Hybridization, washing and scanning of Affymetrix GeneChip mouse genome 430 2.0 arrays was according to standard Affymetrix protocols. Fluorimetric data were processed by Affymetrix GeneChip operating software and the gene chips were globally scaled to all the probe sets with an identical target intensity value. Further analysis was performed by Data Mining Tool (Affymetrix).
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S. Mandard et al. Glycogen synthase 2: novel PPAR target gene 3T3-L1 adipogenesis assay. 3T3-L1 fibroblasts were grown in DMEM plus 10 % calf serum and plated for final differentiation in DMEM plus 10 % FCS. At 2 days after reaching confluence, the medium was changed and the following compounds were added: isobutyl methylxanthine (0.5 mM), dexamethasone (1 mM), and insulin (5 mg/mL). After 3 days, the medium was changed to DMEM plus 10 % FCS and insulin (5 mg/mL). After 6 days the medium was changed to DMEM plus 10 % FCS, which was changed every 3 days. Primary mouse or rat hepatocyte isolation. Primary mouse and rat hepatocytes were isolated as described previously [29] . Briefly, after cannulation of the portal vein, the liver was perfused with calcium-free HBSS, which was pre-gassed with 95 % O 2 /5 % CO 2 . Next, the liver was perfused with a collagenase solution until swelling and degradation of the internal liver structure was observed. The hepatocytes were released, filtered and washed several times using Krebs buffer. Transactivation assay. The proximal part of the mouse Gys-2 promoter was PCR amplified from mouse genomic DNA (strain C57BL/6) using the forward primer: 5' CTTGCTGCCTTTCAG-GAGAGGGCAG 3' and reverse primer: 5' TTCTCTTTAGC-CATTAAGATAG 3'. The resulting 553-bp fragment was used for a second PCR amplification step introducing HindIII and KpnI sites, which were used for subcloning into the pGL-3 Basic vector (Invitrogen). A 156-bp nucleotide fragment surrounding the putative PPRE within the mGys-2 promoter was PCR amplified from mouse genomic DNA (strain C57BL/6) and subcloned into KpnI/BglII sites of the pGL3 SV40 promoter vector (pGL3-tk-LUC, Promega, Leiden, The Netherlands) using the forward primer: 5AAATCG-CAGCTGAAACCT 3', and reverse primer: 5' CTCCTGCTTGTGCTTCTGC 3'. A 314-nucleotide fragment surrounding the putative PPRE within intron 1 of the mouse Gys-2 gene was PCR amplified from mouse genomic DNA (strain C57BL/6) and subcloned into the KpnI and BglII sites of the pGLTk-Luc reporter gene. Reporter vectors were transfected into human hepatoma HepG2 cells, together with an expression vector (pSG5) for mPPARa, mPPARb, or mPPARg1, in the presence or absence of Wy14643 (50 mM), L-165041 (5 mM), or rosiglitazone (5 mM), respectively. Transfections were carried out using the calcium-phosphate precipitation method. A b-galactosidase reporter vector was co-transfected to normalize for differences in transfection efficiency. Luciferase activity was measured 24 h post transfection using the Promega luciferase assay kit (Promega) on a Fluoroskan Ascent Fl apparatus (Thermo labsystems, Breda, The Netherlands). b-Galactosidase activity was measured in the cell lysate by a standard assay using 2-nitrophenyl-bD-galactopyranoside as a substrate. To disable the mouse Gys-2 PPRE within the mGys-2 promoter, two separate (A and B) partially overlapping PCR fragments were generated using the wild-type mGys-2 promoter as a template. Primers sets used to generate part A of the mutated mGys-2 promoter fragment were: 5'-TTTGGTCTAAAGGCCTTTGGCCAAAGG-3' and 5'-CTTGCTGCCTTTCAGGAGAGGGC AG-3'. Primers sets used to generate part B of the mutated mGys-2 promoter fragment were: 5'-CCTTTGGCCAAAGGCCTTTA-GACCAAA-3' and 5'-TTCTCTTTAGCCATTAAGATAGG-GATTG-3'. PCR was carried-out using the two upper DNA fragments and the following primers: 5'-cccaagcttCTTGCTGCCTTTCAGGAG-3' and 5'-ggggtaccTTCTCTTTAGCCATTAAGATAG-3'. The PCR fragment was subsequently cloned into the pGL3 basic reporter vector (HindIII/KpnI cloning site) and verified by automated sequencing. The hHNF4a expression plasmid was constructed by amplifying human hepatoma HepG2 cDNA using the following primers, forward primer 5'-GAATGCGACTCTCCAAAACC-3' and reverse primer 5'-ATCCTTCCCATTCCTGCTCT-3', followed by subcloning of the resulting PCR product into an pGEM-Teasy vector (Promega). The insert was excised by NotI digestion and further subcloned into pcDNA3.1/V5-HisA (Invitrogen). The nucleotide sequence was verified by automated sequencing. Gel shift. hRXRa and mPPARg proteins were generated from pSG5 expression vectors, using the TNT coupled in vitro transcription/translation system (Promega). The following oligos were annealed to generate the double-stranded DNA probe; for DR1int: 5'-CAGGACTTTGGTGACCTCTGGCCTATAT-3' and 5'-ACACATATAGGCCAGAGGTCACCAAAGTC-3'. For nonspecific competition, the following primers were used: etsF 5'-TGGAATGTACCGGAAATAACACCA-3', etsR 5'-TGGTGTTATTTCCGGTACATTCCA-3'.
Oligonucleotides were annealed and labeled by Klenow filling (New England Biolabs, Leusden, The Netherlands) using Redivue [a-
32 P]dCTP (3000 Ci/mmol; Amersham, Roosendaal, The Netherlands). In vitro-translated proteins (0.5-0.8 ml/reaction) were pre-incubated for 15 min on ice in 1 binding buffer (80 mM KCl, 1 mM DTT, 10 mM Tris-HCl pH 7.4, 10 % glycerol, plus protease inhibitors) in presence of 2 mg poly[dI.dC], 5 mg sonicated salmon sperm DNA and competitor oligonucleotides in a final volume of 20 ml. Then 1 ng (1 ng/ml) of radiolabeled oligo was added and incubation was continued for another 10 min at room temperature. Complexes were separated on a 4 % polyacrylamide gel (acrylamide/bisacrylamide 37.5:1) equilibrated in 0.5 TBE at 25 mA. Chromatin immunoprecipitation. Chromatin immunoprecipitation (ChIP) on 3T3-L1 cells and mouse liver was carried out as described previously [11] . Sequences of primers used for PCR were 5'-TCTGGCAGGCATAAGGACCCGAGTT-3' and 5'-GGAAGCCAGGACAGAGTGCAAATACAAT-3' for DR-1int (Intron). For DR-1prom, the following primers were used: 5'-AAAACTGCTTGTGTCTGAGGGAAAC-3' and 5'-AGAG-GACAGACTGAGCATGACAAGAG-3'. Control primers used were 5'-GCTGCGAGATCCATCACCCACTAAAC-3' and 5'-AGCCATCTCACCAGCCCCAACTT-3'. Antibodies against PPARs were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). ChIP on rat hepatocytes was done using a commercially available kit (Active Motif, Rixensart, Belgium). The HNF4a antibody was from Tebu-Bio (Heerhugowaard, The Netherlands). The primers used to amplify the sequence surrounding the DR1prom were 5'-GAATGCCGCTGTGCCTGAGGGAAAC-3' and Research Article 1147 from frozen liver were made and analyzed for glycogen accumulation using the periodic acidÀSchiff (PAS) reaction. Hematoxylin and eosin staining of liver cryosections was done using standard protocols. Western blot. A mouse anti-glycogen synthase monoclonal antibody was used (clone GS-7H5 MAB3106) (Chemicon International, Hampshire, UK). Western blotting was carried out as previously described [4] . The primary antibody was used at a dilution of 1:1000 and the secondary antibody (anti-mouse IgG, Dako, Glostrup, Denmark) was used at a dilution of 1:8000.
Results
Expression of Gys-2 in WAT is regulated by PPARs.
Our initial aim was to identify novel putative target genes of PPARb/d in WAT. Accordingly, we compared gene expression in WAT of wild-type versus PPARb/ d-/-mice using Affymetrix micro-array analysis. The expression of several genes involved in glucose and lipid metabolism was down-regulated in PPARb/d-/-mice, including PPARg, PGC-1a, and GLUT4, which was confirmed for several genes by real-time quantitative PCR (qPCR) ( Table 1) . Expression of Gys-2 was most significantly down-regulated in PPARb/d-/-mice, and therefore Gys-2 was selected for more detailed investigation. Q-PCR confirmed the marked down-regulation of Gys-2 mRNA in WAT of PPARb/ d-/-mice (Fig. 1a) . Furthermore, expression of Gys-2 also appeared to be down-regulated in WAT of PPARg+/-and PPARa-/-mice, although the former result did not achieve statistical significance. In PPARb/d-/-mice, the decrease in Gys-2 mRNA was paralleled by a significant down-regulation of PPARa and PPARg expression, while in PPARa -/-mice expression of PPARb/d was significantly down-regulated (Fig. 1b) . These data show that PPARs are crucial for maintaining Gys-2 expression in fat, although it is difficult to ascertain which PPAR isotype is the main regulator of Gys-2 expression in WAT. To investigate whether expression of Gys-2 in adipocytes is under direct control of PPARs, the effect of PPAR ligands on Gys-2 mRNA was studied in differentiated mouse 3T3-L1 adipocytes. It was observed that the PPARb/d agonist L165041, and the PPARg agonists ciglitazone and rosiglitazone significantly induced Gys-2 mRNA levels (Fig. 1c) . This effect was confirmed at the protein level (Fig. 1d) . Thus, Gys-2 may represent a direct target gene of PPARg and PPARb/d in adipocytes.
PPARa governs Gys-2 hepatic expression. A link between PPARs and glycogen has been previously made. It was observed that liver glycogen levels were reduced in refed PPARa-/-mice compared to refed wild-type mice [30, 31] , which we confirmed using histochemical staining (Fig. 2) . Furthermore, hepatic expression of Gys-2 was decreased in PPARa-/-mice [32] . Expression of Gys-2 is highest in liver, followed by WAT (our unpublished data). We confirm that hepatic Gys-2 mRNA is markedly reduced in PPARa-/-mice; however, only in the 24-h fasted and refed state (Fig. 3a) . To further examine the role of PPARa in Gys-2 expression, primary hepatocytes from wild-type and PPARa-/-mice were treated with the synthetic PPARa agonist Wy14643, allowing for a 
Research Article direct evaluation of the effect of PPARa activation on Gys-2 expression. Basal expression of Gys-2 was about fourfold reduced in PPARa-/-hepatocytes, indicating a requirement for PPARa (Fig. 3b) . Furthermore, Wy14643 stimulated Gys-2 expression in wild-type but not in PPARa-/-hepatocytes (Fig. 3b) . Induction of Gys-2 expression by synthetic PPARa agonists was also observed in rat primary hepatocytes (Fig. 3c) . Together, these data suggest a direct role of PPARa in governing hepatic Gys-2 expression.
Identification of a putative PPRE in the proximal promoter of the mouse Gys-2 gene. To determine what genomic region could be responsible for the PPAR-induced up-regulation of Gys-2 mRNA, the mouse Gys-2 gene was scanned for potential PPREs (NUBIScan algorithm and Hidden Markov Model framework) [33, 34] . A Direct Repeat-1 motif (DR1prom) was localized to the proximal Gys-2 gene promoter, about 169 bp upstream from the transcription start site. With the exception of two nucleotides, DR-1prom is identical to the consensus sequence, suggesting that this sequence could serve as a functional PPRE (Fig. 4a) . DR-1prom was conserved between mouse and rat.
To examine whether the promoter region containing the putative PPRE is responsible for PPAR-dependent up-regulation of Gys-2 expression, a 553-nucleotide fragment of the mouse Gys-2 promoter gene was cloned in front of a luciferase reporter gene and transactivation studies were carried out in HepG2 cells. Surprisingly, co-transfection of PPARa or PPARg1 expression vectors in combination with PPAR agonists slightly decreased luciferase activity, while PPARb/d activation had little effect (Fig. 4b) .
Transactivation assays performed with a small genomic fragment surrounding DR-1prom cloned in front of SV40-luciferase led to a similar overall PPARmediated repression for PPARa and PPARg1, while PPARb/d had little effect (Fig. 4c) . Co-transfection of RXR or of different co-activators such as CBP and PGC1a did not change this pattern (data not shown). Thus, the PPRE identified in the Gys-2 promoter probably does not mediate the effect of PPARs on Gys-2 expression. Nevertheless, ChIP experiments carried out in 3T3-L1 cells indicated that (1) PPARg was bound to DR-1prom in mature adipocytes, but not in pre-adipocytes (Fig. 4d) , and (2) PPARb/d was bound to DR-1prom in pre-adipocytes and, more strongly, in mature adipocytes (Fig. 4e) . Thus, despite DR-1prom behaving poorly as a PPRE in classical transactivation assay, it binds both PPARg and PPARb/d in adipocytes. This suggests that in vivo binding of PPARg and PPARb/d to DR-1prom does not translate into transcriptional activation of the Gys-2 gene, and accordingly that activation of Gys-2 expression by PPARs may be mediated by another genomic region. It should be mentioned that ChIP did not reveal any binding of PPARa to DR-1prom in hepatocytes (data not shown). Interestingly, using the same strategy as described above, a putative PPRE that is homologous to the consensus DR-1 sequence was identified in intron 1 of the mouse Gys-2 gene (Fig. 4a) . To assess whether DR-1int was able to mediate PPAR-dependent transactivation, a 314-nucleotide genomic fragment surrounding DR-1int was cloned in front of the SV40 promoter followed by a luciferase reporter gene. In HepG2 cells treatment with the synthetic PPARa agonist Wy14643 induced reporter activity and this activation was further enhanced upon co-transfection of mPPARa (Fig. 5a ). Similar inductions of reporter activity were observed for PPARb/d and PPARg and their respective agonists (Fig. 5a) . Thus, DR-1int is able to mediate PPAR-dependent transactivation, irrespective of the PPAR isotype, suggesting that it may at least be partially responsible for PPARdependent regulation of Gys-2 expression.
In agreement with the transactivation data, PPARa, PPARb/d and PPARg proteins were able to specifically bind DR-1int in gel shift experiments. A retarded heterodimeric complex was observed only in the presence of both PPAR and obligate binding partner RXRa (Fig. 5b) . The complex disappeared in the presence of an excess of cold specific oligonucleotide, but not nonspecific oligonucleotide. Examination of in vivo PPAR binding to DR-1int by ChIP yielded very similar results as for DR-1prom: PPARg was bound to DR-1int in mature 3T3-L1
adipocytes, but not in pre-adipocytes (Fig. 6a) , whereas PPARb/d was bound to DR-1int in both pre-and mature adipocytes (Fig. 6b) . In liver, ChIP analysis demonstrated binding of PPARa to DR-1int in wildtype but not PPARa -/-mice, and binding was enhanced by fasting and Wy14643 (Fig. 6c) . Together, these data indicate that mouse Gys-2 is a direct PPAR target gene and that regulation by PPARs is at least partially mediated by a PPRE present in intron 1.
Gys-2 is a novel direct target of the liver enriched factor HNF4a. As explained above, PPARa caused a reduction in Gys-2 promoter activity via DR-1prom (Fig. 4b, c) . A similar decrease of promoter activity in response to PPARa despite the presence of a putative PPRE has been reported for other genes. Indeed, it was found that PPARa decreases expression of the Research Article apoCIII and transferrin genes via competition with the HNF4a. Since HNF4a is known to recognize DR-1 sequences as well, we examined whether HNF4a might control the expression of Gys-2 in liver, possibly via DR-1prom. Gys-2 mRNA levels were markedly decreased in liver-specific HNF4a-null mice, thus supporting a role for HNF4a in regulating Gys-2 expression (Fig. 7a) . In transactivation assays using the Gys-2 promoter, HNF4a markedly activated reporter activity, suggesting the presence of a HNF4a response element within the 0.55-kb promoter fragment (Fig. 7b) . Mutating DR-1prom resulted in an approximately 50 % reduction in HNF4a-dependent activation of the Gys-2 promoter (Fig. 7c) , which suggests that (a) HNF4a responsiveness is partially mediated by DR-1prom, or (b) the mutations with DR-1prom only partially disabled HNF4a responsiveness. Regardless of these explanations, these data suggest that HNF4a directly regulates the hepatic expression of Gys-2 at least partially via DR-1prom. Finally, ChIP clearly showed HNF4a binding to DR1prom but not DR-1int in rat primary hepatocytes (Fig. 7d) .
Cross-talk between PPARa and HNF4a in the transcriptional control of Gys-2. Whereas HNF4a activates the Gys-2 promoter via DR-1prom, PPARa does the opposite, suggesting that PPARa may interfere with Gys-2 promoter activation by HNF4a. To examine whether this is the case, the effect of PPARa on HNF4a-mediated transactivation of the 0.55-kb Gys-2 promoter was studied. PPARa activa- tion significantly reduced HNF4a-dependent transactivation, indicating competition between HNF4a and PPARa in the regulation of the Gys-2 promoter (Fig. 7e) . As already mentioned above, we failed to find any evidence for binding of PPARa to DR-1prom in hepatocytes. Thus, the inhibitory effect of PPARa on transcriptional activation of Gys-2 by HNF4a likely does not occur via competition with HNF4a for actual binding to DR-1prom.
Discussion
In the present study, we have identified the mouse Gys-2 gene as a direct PPAR and HNF4a target gene. We have shown that the effects of PPARs and HNF4a on Gys-2 expression occur via two distinct response elements. Indeed, while transcriptional activation of the Gys-2 gene by PPARs was found to be mediated by a PPRE present in intron 1 of the mGys-2 gene (DR1int), the stimulatory effect of HNF4a was mediated by a response element in the immediate upstream promoter (DR-1prom).
Our data are suggestive of the following scenario. In liver, which expresses high amounts of HNF4a, DR1prom is occupied by HNF4a but not PPARa, while DR-1int is bound by PPARa but not HNF4a. Hence, HNF4a and PPARa activate Gys-2 expression via different response elements. Nevertheless, important negative cross-talk between the two nuclear receptors was observed. In the absence of any mutual binding to the response elements, it can be hypothesized that competition may take place at the level of binding to common co-activator proteins in a mechanism that is often referred to as squelching. In adipose tissue, which does not express HNF4a, DR-1prom is occupied by PPARb/d and PPARg, but this does not result in transcriptional activation. Rather, transactivation occurs via binding of PPARb/d and PPARg to DR1int.
Our data indicate that HNF4a is an extremely powerful activator of mouse Gys2 transcription, explaining the marked reduction in hepatic Gys-2 expression in liver-specific HNF4a-null mice [35] . As mentioned above, regulation of mGys-2 expression by HNF4a at least partially occurs via DR1prom. A recent study that combined ChIP with promoter micro-arrays showed that the Gys-2 promoter is bound by HNF4a in human liver [36] , thus establishing Gys-2 as a direct target of HNF4a in human as well. It is not very clear why disabling the DR-1prom reduced HNF4a-dependent transactivation by only 50 %. It is possible that the 0.55-kb Gys-2 promoter fragment contains an additional HNF4a response element, although in silico analysis failed to reveal such an element. Alternatively, Cell. Mol. Life Sci. Vol. 64, 2007 it is possible that mutating the wild-type DR-1prom (AGGCCAAAGGCCA) into a mutated DR1prom (AGGCCTTTGGCCA) only partially disabled the response element. While functional PPREs are commonly located within regulatory sequences, i.e., proximal promoters, PPREs have also been identified in intronic sequences. Examples are PPREs within intron 3 of human/ mouse Angptl4 and rat peroxisomal thiolase B genes, and within intron 1 of the rat acyl-CoA binding protein gene and human carnitine palmitoyltransferase 1A [2] [3] [4] [5] . Our data demonstrate that regulation of Gys-2 expression by PPARs is also mediated by an intronic PPRE.
In the past few years, our understanding of the function of PPARb/d in vivo has improved greatly thanks to studies using various transgenic mouse models [19, 37] . At the level of metabolism, PPARb/ d over-expression promotes skeletal muscle fatty acid oxidation and type I fiber content in mice, resulting in improved endurance exercise performance [22] . Conversely, deletion of PPARb/d in cardiomyocytes is associated with impaired fatty acid oxidation and expression of fatty acid oxidative genes, whereas glucose uptake is increased [38] . In WAT, PPARb/d stimulates fatty acid oxidation and uncoupling, thereby diminishing adiposity [21] . It is thus clear that PPARb/d plays a pivotal role in governing fatty acid oxidation in a variety of tissues. In contrast, data linking PPARb/d to regulation of glucose homeostasis remain scarce [20, 39, 40] . Our data reveal that PPARb/d is a critical regulator of the adipose expression of the Gys-2 gene. Furthermore, micro-array and qPCR analysis indicated that expression of numerous other genes involved in lipid and glucose metabolism was markedly down-regulated in PPARb/d-null mice, including GLUT4, p85, and CD36. Since PPARg and PGC-1a were significantly down-regulated as well, it is possible that many of the observed changes are not linked to the absence of PPARb/d per se but rather reflect indirect effects mediated via decreased PPARg and PGC-1a mRNA. Although such an effect may contribute to some extent to the down-regulation of Gys-2 in PPARb/d-null mice, the in vitro studies leave no doubt that Gys-2 is a direct target gene of PPARb/d, as well as of PPARg. Glycogen is stored in many tissues, yet it is particularly abundant in liver, muscle, and adipose tissue. In liver, glycogen serves to maintain blood glucose levels between meals, while skeletal muscle glycogen is used to fuel muscle contractions. In contrast, adipose tissue glycogen serves as a source of glycerol 3-phosphate, which is required for (re)-esterification of fatty acids into triglycerides [41] . Several alternative pathways exist to produce glycerol 3-phosphate, including synthesis from glucose, and conversion of gluconeogenic precursors (glyceroneogenesis). Since expression and activity of glycerol kinase are very low in adipose tissue [42] , direct phosphorylation of glycerol is not considered as a major pathway to generate glycerol 3-phosphate. However, recent studies suggest that this may change after treatment with synthetic PPARg agonists, which markedly up-regulate glycerol kinase expression in human and mouse adipocytes [11, 42] . In fact, it has been hypothesized that stimulation of glycerol kinase expression by TZDs, resulting in increased fatty acid re-esterification, may at least partially account for the suppressive effect of TZDs on plasma free fatty acid levels. Stimulation of fatty acid esterification is part of a general lipogenic and adipogenic effect of PPARg in the adipocyte. Since adipose glycogen stores yield glycerol 3-phosphate as a precursor for fatty acid (re-)esterification, up-regulation of Gys-2 expression by PPARg can be placed in the context of the lipogenic role of PPARg in the adipocyte, which is aimed at promoting energy storage. Besides contributing to lipogenesis, synthesis of glycogen permits continued uptake of glucose into cells. Accordingly, it can be speculated that upregulation of adipose Gys-2 by PPARg might partially account for the stimulation of glucose uptake into adipocytes by PPARg agonists.
It is currently still ambiguous whether PPARb/d serves a general anabolic or catabolic function in the adipocyte. On the one hand, it has been reported that PPARb/d promotes fatty acid oxidation in adipocytes [20, 21] . On the other hand, PPARb/d also seems to have a facilitative, yet important role in lipo-and adipogenesis [43] . As discussed above for PPARg, up-regulation of Gys-2 expression by PPARb/d may indicate a role for PPARb/d in fatty acid (re-)esterification, thus contributing to a lipogenic role for PPARb/d. The highest levels of glycogen are found in liver and fluctuate with nutritional status. The hepatic synthesis of glycogen from glucose is catalyzed by Gys-2 [44] . Remarkably, expression of Gys-2 in liver increases during fasting, at the same time when glycogen stores are actively broken down [32] . The reason behind this seemingly counterintuitive regulation is not very Research Article clear, but it may serve to prime the glucose synthesizing system for when dietary glucose becomes available again. In the absence of PPARa, we observed that the expression of Gys-2 drops markedly during prolonged fasting and refeeding. The reduced Gys-2 expression is likely responsible for the diminished rate of glycogen formation upon refeeding, as observed by us and previously by others. Indeed, the effect of PPARa deletion on liver glycogen is minor except under conditions of refeeding [30] [31] [32] . It has been reported that after a short-term fast the gluconeogenic flux in PPARa-null mice is directed more towards glycogen, leading to a decrease in hepatic glucose output. However, it is unclear what happens to the gluconeogenic flux toward glycogen in the fasted-refed state, although our and other data clearly indicate that total glycogen synthesis is decreased in PPARa-/-mice. Mutation of the GYS2 gene in humans leads to lower hepatic glycogen levels and fasting hypoglycemia [45] , biochemical features that are also observed in PPARa-/-animals [31] . However, opposite to that observed in patients with a dysfunctional GYS2 gene, PPARa-/-mice show low plasma ketones, which is explained by the stimulatory effect of PPARa on fatty acid oxidation and ketogenesis. Overall, our data suggest that the decreased hepatic glycogen levels in PPARa-/-and liver-specific HNF4a-null mice [28, 35] may be due to decreased activation of Gys-2 expression via DR-1int and DR1prom, respectively. Although PPARa and HNF4a stimulate Gys-2 expression via different response elements, important interplay exist between signaling of the two nuclear receptors.
In conclusion, we show that Gys-2 is a direct target gene of PPARs. Transcriptional regulation is achieved via a PPRE present in the first intron. An additional direct repeat response element identified in the Gys-2 promoter mediates transactivation by HNF4a.
